FMT-based discovery: from platform to product
Posted 5th July 2019 by Jane Williams
Fecal microbiota transplant (FMT) is probably the microbiome based therapy that has received the most media attention. It seems journalists love to talk about poo.
This has given momentum to research in the field. As the amount of trial data and fear of antibiotic resistance grows, FMT is now a much more common treatment for conditions like clostridioides difficile infection (CDI).
Outside of specialist researchers in this therapy however, one gets a sense that FMT has been tarnished in the eye of many scientists by the DIY culture that has built up in many parts of the globe. The underlying issue with all microbiome research is that much is still to be learned about the mechanism and relationship to various conditions. That also adds to some being very cautious about committing resources to exploring further.
However, many believe that with the correct approach and data goals, FMT could become much more than a treatment option for CDI or just a “biohack”.
Jos Seegers, Operations Manager at Caelus Health, is responsible for R&D activities within the company as well as outsourced product development, managing the IP portfolio and regulatory affairs. He recently gave a very in depth presentation that covers a great introduction to the therapy, some fascinating insights into the latest developments and research, right through to the future of regulation in the field.
In this free presentation, given at the 6th Microbiome R&D and Business Collaboration Forum: Europe, he discusses:
- FMT as a discovery tool
- Reducing risk in product development
- Data-mining and strain identification
- Preclinical development
- Strain optimization and functional testing
- Formulation development
- In-vivo testing
- Clinical development
- Study design
- Deep metagenomics
The next event in the series is the Microbiome R&D and Business Collaboration Forum: USA, taking place in San Diego on October 29th – 30th. Check out the agenda here.
Leave a Reply